3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy

Synapse

Volumn 55, Issue 3, 2005, Pages 148-155

  Lebsanft, Heike B ^a   Kohles, Timo ^a   Kovar, Karl Artur ^a   Schmidt, Werner J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

6 OHDA; Dopamine; Enantiomers; MDMA; Parkinson's disease; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; HALOPERIDOL; OXIDOPAMINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CIRCLING BEHAVIOR; CONTROLLED STUDY; ENANTIOMER; ENANTIOSELECTIVITY; LATENT PERIOD; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; RIGOR;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CATALEPSY; DENERVATION; DISEASE MODELS, ANIMAL; GAIT DISORDERS, NEUROLOGIC; HALOPERIDOL; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; STEREOISOMERISM;

EID: 13244253906     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20102     Document Type: Article

References (77)

1. Anderson GM 3rd, Braun G, Braun U, Nichols DE, Shulgin AT. 1978. Absolute configuration and psychotomimetic activity. NIDA Res Monogr 22:8-15.
2. Baker LE, Taylor MM. 1997. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol Biochem Behav 57:737-748.
3. Battaglia G, De Souza EB. 1989. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr 94:240-258.
4. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. 1988. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-163.
5. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP. 1998. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol 53:649-655.
6. Bogen IL, Haug KH, Myhre O, Fonnum F. 2003. Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 43:393-400.
7. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. 2002. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249:1-5.
8. Brodkin J, Malyala A, Nash JF. 1993. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 45:647-653.
9. Callaway CW, Wing LL, Geyer MA. 1990. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254:456-464.
10. Cho AK, Hiramatsu M, Distefano EW, Chang AS, Jenden DJ. 1990. Stereochemical differences in the metabolism of 3,4- methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metabol Dispos 18:686-691.
11. Crespi D, Mennini T, Gobbi M. 1997. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121:1735-1743.
12. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G. 2002. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161:356-364.
13. Farfel GM, Vosmer GL, Seiden LS. 1992. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Brain Res 595:121-127.
14. Finnegan KT, Taraska T. 1996. Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo. J Neurochem 66:1949-1958.
15. Fischer HS, Zernig G, Schatz DS, Kumpel C, Sana A. 2000. MDMA ("ecstasy") enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 12:1385-1390.
16. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH. 1997. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19:1271-1283.
17. Glennon RA. 1986. Discriminative stimulus properties of phenylisopropylamine derivatives. Drug Alcohol Depend 17:119-134.
18. Glennon RA, Yousif M, Patrick G. 1988. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol Biochem Behav 29:443-449.
19. Green AR, Cross AJ, Goodwin GM. 1995. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology 119:247-260.
20. Gold LH, Koob GF, Geyer MA. 1988. Stimulant and hallucinogenic behavioral profiles of of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4- methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 247:547-555.
21. Gough B, Ali SF, Slikker W Jr, Holson RR. 1991. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39:619-623.
22. Gudelsky GA, Nash JF. 1996. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
23. Gudelsky GA, Yamamoto BK, Nash FJ. 1994. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 264:325-330.
24. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE. 2002. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300:1093-1100.
25. Hiramatsu M, Cho AK. 1990. Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29:269-275.
26. Hiramatsu M, Nabeshima T, Kameyama T, Maeda Y, Cho AK. 1989. The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol Biochem Behav 33:343-347.
27. Hiramatsu M, Di Stefano E, Chang AS, Cho AK. 1991. A pharmacokinetic analysis of 3,4-methylenedioxymethamphetamine effects on monoamine concentrations in brain dialysates. Eur J Pharmacol 204:135-140.
28. Jaber M, Jones S, Giros B, Caron MG. 1997. The dopamine transporter: a crucial component regulating dopamine transmission. Move Disord 12:629-633.
29. 3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J Pharmacol Exp Ther 262:356-364.
30. 3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269-276.
31. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. 1998. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979-1986.
32. 3H]dopamine-prelabeled rat striatum. Res Com Subst Abuse 9:45.
33. Kehne JH, Ketteler HJ, McCloskey TC, Sullivan CK, Dudley MW, Schmidt CJ. 1996. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15:116-124.
34. Kelland MD, Freeman AS, Chiodo LA. 1990. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253:803-811.
35. Kokotos Leonardi ET, Azmitia EC. 1994. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231-238.
36. Lyon RA, Glennon RA, Titeler M. 1986. 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88:525-526.
37. Mantle TJ, Tipton KF, Garret NJ. 1976. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 29:1347-1354.
38. Margolis J. 2001. Ecstasy's dividend. Time 19:58-59.
39. McDowell DM, Kleber HD. 1994. MDMA: its history and pharmacology. Psychiat Ann 24:127-130.
40. McKenna DJ, Guan XM, Shulgin AT. 1991. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol Biochem Behav 38:505-512.
41. Meyer A, Mayerhofer A, Kovar K-A, Schmidt WJ. 2002. Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ("ecstasy") and 3,4-methylenedioxyethylamphetamine ("eve") isomers in rat brain and blood. Neurosci Lett 330:193-197.
42. Mlinar B, Corradetti R. 2003. Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur J Neurosci 18:1559-1571.
43. Nash JF. 1990. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47:2401-2408.
44. Nash JF, Yamamoto BK. 1992. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 581:237-243.
45. Nash JF Jr, Meltzer HY, Gudelsky GA. 1988. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245:873-879.
46. Nichols DE. 1986. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 18:305-313.
47. 3H]serotonin from rat brain synaptosomes. J Med Chem 25:530-535.
48. Padich RA, McCloskey TC, Kehne JH. 1996. 5-HT modulation of auditory and visual sensorimotor gating. II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology 124:107-116.
49. Paulus MP, Geyer MA. 1991. A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology 104:6-16.
50. Paxinos G, Watson C. 1998. The rat brain in stereotactic coordinates, 4th ed. San Diego: Academic Press.
51. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C. 1985. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229:986-988.
52. Rosecrans JA, Glennon RA. 1987. The effect of MDA and MDMA ('Ecstasy') isomers in combination with pirenpirone on operant responding in mice. Pharmacol Biochem Behav 28:39-42.
53. Rudnick G, Wall SC. 1992. The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89:1817-1821.
54. Sabol KE, Seiden LS. 1998. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res 806:69-78.
55. Schechter MD. 1978. Stimulus properties of d-amphetamine as compared to l-amphetamine. Eur J Pharmacol 47:461-464.
56. Schechter MD. 1987. MDMA as a discriminative stimulus: isomeric comparisons. Pharmacol Biochem Behav 27:41-44.
57. Schmidt CJ. 1987. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7.
58. Schmidt CJ, Levin JA, Lovenberg W. 1987. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36:747-755.
59. Schmidt CJ, Black CK, Abbate GM, Taylor VL. 1990. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529:85-90.
60. Schmidt CJ, Taylor VL, Abbate GM, Nieduzak TR. 1991. 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. J Pharmacol Exp Ther 256:230-235.
61. Schmidt CJ, Sullivan CK, Fadayel GM. 1994. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62:1382-1389.
62. Schmidt WJ, Mayerhofer A, Meyer A, Kovar KA. 2002. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neurosci Lett 330:251-254.
63. Shankaran M, Gudelsky GA. 1998. Effect of 3,4- methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 61:361-366.
64. Shankaran M, Gudelsky GA. 1999. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology 147:66-72.
65. Shulgin AT, Nichols DE. 1978. Characterization of three new psychotomimetics. The pharmacology of hallucinogens. In: Stillman RC, Willette RE editors. The psychopharmacology of hallucinogens. New York: Pergamon Press. p 74.
66. Simantov R. 2004. Multiple molecular and neuropharmacological effects of MDMA (Ecstasy). Life Sci 74:803-814.
67. Sinton CM, Fallon SL. 1988. Electrophysiological evidence for a functional differentiation between subtypes of the 5HT1 receptor. Eur J Pharmacol 157:173-181.
68. Stadtland C, Erfurth A, Arolt V. 2000. De novo onset of Parkinson's disease after antidepressant treatment with citalopram. Pharmacopsychiatry 33:194-195.
69. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36:2297-2303.
70. Stone DM, Johnson M, Hanson GR, Gibb JW. 1988. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4- methylenedioxymethamphetamine. J Pharmacol Exp Ther 247:79-87.
71. Wadenberg ML. 1996. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339.
72. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG. 1997. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19:1285-1296.
73. White SR, Duffy P, Kalivas PW. 1994. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 62:41-50.
74. Yamamoto BK, Spanos LJ. 1988. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148:195-203.
75. Yamamoto BK, Nash JF, Gudelsky GA. 1995. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273:1063-1070.
76. Young R, Glennon RA. 1986. Discriminative stimulus properties of amphetamine and structurally-related phenalkylamines. Med Res Rev 6:99-130.
77. Zetterstrom T, Herrera-Marschitz M, Ungerstedt U. 1986. Simultaneous measurement of dopamine release and rotational behavior in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res 376:1-7.